Nova Patents
PL1639010T3

Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease

Abstract

This record has no abstract on file.

Term

Term ended

Projected expiry passed 28 May 2024, 2.3 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

27 members in 19 offices

This recordMember, by publication datePriority claim9 more offices are in the list below

Priority claims2

Priority claims
DocumentOfficeKindDate
47506703United States of AmericaP
2004016995United States of AmericaW

Members27

Family members, oldest first
DocumentOfficeKind
US2004241169A1United States of AmericaA1
AU2004253865A1AustraliaA1
CA2527373A1CanadaA1
WO2005003298A2World Intellectual Property Organization (WIPO)A2
WO2005003298A3World Intellectual Property Organization (WIPO)A3
MXPA05012832AMexicoA
NO20056027LNorwayL
EP1639010A2European Patent Office (EPO)A2
CN1816567AChinaA
EP1639010A4European Patent Office (EPO)A4
ZA200510125BSouth AfricaB
JP2007502330AJapanA
US7465446B2United States of AmericaB2
US2009074752A1United States of AmericaA1
NZ543768ANew ZealandA
US7744875B2United States of AmericaB2
AU2004253865B2AustraliaB2
IL172028AIsraelA
NO344368B1NorwayB1
EP1639010B1European Patent Office (EPO)B1
PT1639010TPortugalT
DK1639010T3DenmarkT3
SI1639010T1SloveniaT1
PL1639010T3This recordPolandT3
HUE051533T2HungaryT2
ES2813928T3SpainT3
CY1123535T1CyprusT1